Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details

Cannabinoid-focused pharmaceutical company MediPharm Labs Corp. LABS MEDIF MLZ announced Monday its financial results for the three months ended June 30, 2023, revealing revenue of CA$9.58 million ($7.11 million) compared to CA$4.36 million in the same period last year.

“In Q2, we continued to make progress by growing our revenue base, improving gross margins, reducing expenses and reducing cash burn as we drive towards profitability.” Greg Hunter, CFO, MediPharm Labs stated. “We have also demonstrated that we can quickly integrate and drive synergies through acquisitions."

Q2 Financial Summary

• Gross profit amounted to CA$855,000, compared to $387,000 in the prior quarter and gross loss of $532,000 in the same period of 2022.
• Adjusted EBITDA was a loss of CA$3.19 million, compared to adjusted EBITDA loss of CA$6.35 million in the second quarter of last year.
• The company ended second quarter with CA$14.7 million in cash and cash equivalents with approximately CA$3 million of debt.
• Net loss amounted to CA$2.7 million, compared to net loss of CA$8.99 million



Recent Milestones

• MediPharm completed its first commercial delivery to the United States. The delivery was comprised of clinical trial material for a fully funded large-scale phase two clinical trial.
• On April 1st, 2023, the company closed the acquisition of VIVO Cannabis Inc. ("VIVO") in an all equity business combination.

See Also: MediPharm Labs Begins Restructuring Following Acquisition Of VIVO, Reduces Non-Direct Labor Workforce By ~30%

David Pidduck, CEO, MediPharm Labs commented, "We are very happy with our Q2 performance lead by the smooth VIVO integration that is ahead of all cost synergy targets. We are excited to have new employees, new business units, new products and capabilities and new investors and stakeholders."

Price Action 

MediPharm shares were trading 7.97% lower at $0.0589 per share at the time of publishing Monday morning. 

Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Courtesy of Terrance Barksdale via Pexels